Abstract
Novel NO-donor-caffeic acid hybrids with antioxidant, nitric oxide release and vasodilator properties were designed and synthesized through a symbiotic approach using caffeic acid and three different NO-donating groups such as nitric ester, 4-hydroxyl-3-phenylfuroxan and 4-hydroxymethyl-3-phenylsulfonylfuroxan. The antioxidant activities of these hybrid products were assessed by DPPH assay and by detecting the TBARS produced in the ferrous salt/ascorbate induced autoxidation of lipids which were present in microsomial membranes of rat hepatocytes. The nitric oxide release activities were assessed by indirect evaluation of the produced nitrite. The vasodilator activities were determined through an in vitro vascular relaxation assay (organ bath) using PGF2α-precontracted porcine pulmonary arteries. The results showed that the target phenylsulfonylfuroxan 12, especially 12a while keeping the antioxidant activity, showed more NO release activity and vasodilating activity than isosorbide dinitrate (ISDN). Thus 12a may be considered as a novel potent anti-atherosclerosiss drug candidate.
Keywords: Atherosclerosis, Nitric oxide donor, Caffeic acid, Antioxidant activity, Nitric oxide release, Vasodilator activity, LDL, Acid Hybrids, Anti-Atherosclerotic, Moiety, reactive oxygen species (ROS), vasodilation, isoproterenol (ISO), myocardial infarction, dibromoalkanes, lipid autooxidation
Letters in Drug Design & Discovery
Title: Design, Synthesis and Biological Study of Novel NO-Donor-Caffeic Acid Hybrids as Potential Anti-Atherosclerotic Drug Candidates
Volume: 8 Issue: 6
Author(s): Nian-Guang Li, Rong Wang, Yu-Ping Tang, Zhi-Hao Shi, Bao-Quan Li, Wei Li, Jian-Ping Yang, Zhen-Jiang Wang, Shu-Lin Song, Li-Hua Qian, Li-Juan Yao, Jun-Zuan Xia, Jia Xu, Feng Feng, Da-Wei Qian and Jin-Ao Duan
Affiliation:
Keywords: Atherosclerosis, Nitric oxide donor, Caffeic acid, Antioxidant activity, Nitric oxide release, Vasodilator activity, LDL, Acid Hybrids, Anti-Atherosclerotic, Moiety, reactive oxygen species (ROS), vasodilation, isoproterenol (ISO), myocardial infarction, dibromoalkanes, lipid autooxidation
Abstract: Novel NO-donor-caffeic acid hybrids with antioxidant, nitric oxide release and vasodilator properties were designed and synthesized through a symbiotic approach using caffeic acid and three different NO-donating groups such as nitric ester, 4-hydroxyl-3-phenylfuroxan and 4-hydroxymethyl-3-phenylsulfonylfuroxan. The antioxidant activities of these hybrid products were assessed by DPPH assay and by detecting the TBARS produced in the ferrous salt/ascorbate induced autoxidation of lipids which were present in microsomial membranes of rat hepatocytes. The nitric oxide release activities were assessed by indirect evaluation of the produced nitrite. The vasodilator activities were determined through an in vitro vascular relaxation assay (organ bath) using PGF2α-precontracted porcine pulmonary arteries. The results showed that the target phenylsulfonylfuroxan 12, especially 12a while keeping the antioxidant activity, showed more NO release activity and vasodilating activity than isosorbide dinitrate (ISDN). Thus 12a may be considered as a novel potent anti-atherosclerosiss drug candidate.
Export Options
About this article
Cite this article as:
Li Nian-Guang, Wang Rong, Tang Yu-Ping, Shi Zhi-Hao, Li Bao-Quan, Li Wei, Yang Jian-Ping, Wang Zhen-Jiang, Song Shu-Lin, Qian Li-Hua, Yao Li-Juan, Xia Jun-Zuan, Xu Jia, Feng Feng, Qian Da-Wei and Duan Jin-Ao, Design, Synthesis and Biological Study of Novel NO-Donor-Caffeic Acid Hybrids as Potential Anti-Atherosclerotic Drug Candidates, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906848
DOI https://dx.doi.org/10.2174/157018011795906848 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design The Use of Genomics and Proteomics for the Recognition of Transplantation Rejection of Solid Organs
Recent Patents on DNA & Gene Sequences Adult Stem Cells and Extracellular Vesicles in Acute and Chronic Kidney Injury
Current Regenerative Medicine (Discontinued) Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: A Two-Faced Janus
Current Respiratory Medicine Reviews Acute Renal Failure - A Serious Complication in Patients After Kidney Transplantation
Current Medicinal Chemistry Non-Viral Gene Delivery Methods
Current Pharmaceutical Biotechnology Emerging Nanocarriers-based Approaches to Diagnose and Red uce Vascular Inflammation in Atherosclerosis
Current Medicinal Chemistry Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Lipid Engineered Nanoparticle Therapy for Burn Wound Treatment
Current Pharmaceutical Biotechnology Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design Editorial (Hot Topic: No Reflow: What’s in a Name?)
Current Pharmaceutical Design The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Antioxidant Enzyme Mimics with Synergism
Mini-Reviews in Medicinal Chemistry Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Development of Monoclonal Antibodies that Inhibit Platelet Adhesion or Aggregation as Potential Anti-Thrombotic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design